$19.30+ Bn Neutropenia Treatment Market to Grow at 5.4% CAGR, Globally, by 2027

North America region dominated the market

By region, the global neutropenia treatment market across North America held the largest share in 2019, accounting for nearly half of the market. This is attributed to increase in incidences of leukemia in the region. Nevertheless, the Europe region is expected to register the highest CAGR of 5.8% during the forecast period.

Allied Market Research recently published a report, “Neutropenia Treatment Market by Treatment (Colony-stimulating factors, Antibiotics, Antifungals, and Antivirals), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2020–2027″. According to the report, the global neutropenia treatment market was pegged at $12.60 billion in 2019, and is anticipated to hit $19.30 billion by 2027, growing at a CAGR of 5.4% from 2020 to 2027.

Key Market Players

PARTNER THERAPEUTICS, INC., AMGEN INC., SPECTRUM PHARMACEUTICALS, INC., PFIZER INC., TEVA PHARMACEUTICAL INDUSTRIES LTD., COHERUS BIOSCIENCES, INC., NOVARTIS AG, MYLAN N.V., BEYONDSPRING INC., CELLERANT THERAPEUTICS, INC., KYOWA KIRIN

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/6663

The colony stimulating factor segment to manifest highest growth through 2027

In the realm of neutropenia treatment, the colony stimulating factor segment is poised for remarkable growth, with a projected fastest Compound Annual Growth Rate (CAGR) of 5.5% throughout the forecast period. Notably, this segment already claimed the lion’s share in 2019, accounting for over four-fifths of the global market dedicated to neutropenia treatment. This dominance is attributed to the presence of influential industry players dedicated to advancing neutropenia drugs. Additionally, the surging prevalence of leukemia is anticipated to heighten the risk of neutropenia, particularly following chemotherapy, further propelling the expansion of this segment.

Hospital Pharmacies Secure the Leading Position

Within the spectrum of end-users, hospital pharmacies established their dominance in the global neutropenia treatment market in 2019, contributing to approximately two-fifths of the overall revenue. On the other hand, the online segment is primed to exhibit the most substantial CAGR of 6.0% during the forecast period. This surge is primarily fueled by the ever-increasing utilization of the Internet, the growing popularity of online platforms, and the escalating preference for eCommerce channels on a global scale.

The hospital pharmacies segment held the largest share

By end user, the hospital pharmacies segment dominated the global neutropenia treatment market in 2019, contributing to around two-fifth of the total revenue. On the other hand, the online segment is expected to register the highest CAGR of 6.0% during the forecast period. This is owing to surge in the use of Internet, increase in popularity, and rise in preference of eCommerce channels across the globe.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/6663